1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Boryung Corporation

Boryung Corporation

003850.KS
Boryung CorporationKR flagKorea Exchange
8,650.00
KRW
+40.00
- -
730.76BMarket Cap
Boryung Corporation
003850.KS
(Korea Exchange)

Recent

price

8,650.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5,108.58
5,515.45
5,103.67
5,377.59
5,922.63
6,615.71
47,774.72
1,477.95
8,136.39
8,438.22
7,898
10,040.72
11,544.8
13,043.16
14,898.76
12,119.97
12,297.77
Revenue per Share
231.68
110.63
153.74
232.12
355.71
334.64
655.55
198.23
358.87
518.62
377.51
689
636
610
1,020
766
1,255.62
Basic EPS, GAAP
-278.72
-116.64
63.45
253.59
-121.38
-52.87
-2,039.42
-320.42
-321.89
-350.17
-166.64
13.6
-1,444.95
286.4
886.36
1,229.77
1,503.09
Free Cash Flow per Basic Share
20.08
33.39
10.6
16.6
17.49
24.41
181.75
5.66
120.17
40.6
59.09
72.21
100.02
99.94
99.12
100.02
- -
Dividend per Share
1,697.31
2,419.51
2,367.65
2,623.86
2,949.64
3,268.36
23,706.37
900.2
4,634.75
4,649.18
4,492.89
5,909.25
6,232.18
6,695.59
7,471.07
6,697.15
7,030.6
Book Value per Share
2,078.65
2,232.26
2,112.2
2,341.88
2,647.33
2,924.46
20,734.02
811.65
4,218.19
4,301.89
4,000.44
6,106.5
5,051.85
5,710.9
9,220.41
8,359.68
8,736.22
Tangible Book Value per Share
59
56
61
61
61
61
9
286
57
62
71
62
66
66
68
84
84
Basic Weighted Avg Shares
300,959
308,006
312,075
327,279
359,491
401,350
409,140
422,721
460,402
524,269
561,867
627,279
760,476
859,626
1,017,107
1,017,427
1,032,231
Sales/Revenue/Turnover
5.74
3.16
1.08
5.85
6.8
6.86
5.38
0.24
5.42
7.45
7.12
6.61
7.44
7.94
6.93
6.4
7.2
Operating Margin (%)
7,827
9,318
10,485
10,553
11,125
12,781
15,320
16,257
16,142
17,428
27,566
32,074
37,644
44,387
42,849
43,522
44,219
Depreciation Expense
13,649
6,178
9,401
14,127
21,591
20,301
5,614
56,699
20,307
32,222
26,856
43,044
41,894
40,203
69,633
64,303
105,392
Net Income, GAAP
25.56
17.52
- -
30.46
24.55
27.02
73.84
26.06
23.57
24.13
25.48
39.03
28.76
28.58
- -
7.94
16.83
Effective Tax Rate (%)
4.54
2.01
3.01
4.32
6.01
5.06
1.37
13.41
4.41
6.15
4.78
6.86
5.51
4.68
6.85
6.32
10.21
Profit Margin (%)
45,879
42,886
47,832
65,248
79,335
82,635
66,410
112,342
94,809
92,637
192,789
281,361
60,895
176,576
392,234
407,973
415,228
Working Capital
300
100
- -
- -
2,482
1,250
- -
27,400
54,291
72,587
170,400
189,231
94,552
152,582
126,338
259,103
232,280
LT Debt
132,481
137,970
145,793
159,980
177,356
195,940
195,349
249,654
256,103
282,954
340,288
474,314
516,417
549,253
784,503
845,503
873,714
Total Equity
8.79
4.57
- -
6.78
8.95
8.48
2.28
0.27
5.81
8.07
6.45
4.07
5.57
6.44
- -
5.55
5.8
Return on Invested Capital (%)
13.16
5.2
- -
7.87
11.02
8.97
2.42
20.71
6.06
8.77
6.53
8.33
7.67
7.43
- -
9.54
15.16
Return on Capital (%)
14.62
5.26
6.72
9.28
12.75
10.76
2.8
24.63
7.81
11.69
8.83
12.5
10.75
9.44
14.64
11.99
19.46
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
68,484
70,917
55,623
LT Borrowings
249,856
244,668
218,230
LT Finance Leases
15,435
14,435
14,050
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
84
84
84
Market Capitalization
732,157
756,506
755,428

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
609,336
662,938
672,409
Cash, Cash Equivalents & STI
181,415
254,683
263,936
Accounts Receivable, Net
172,492
168,445
154,728
Inventories
228,492
219,444
237,229
Total Current Liabilities
254,960
254,965
257,181
Payables & Accruals
- -
- -
- -
ST Debt
68,484
70,917
55,623
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.61%
21.05%
7.78%
Free Cash Flow
-1,047.18%
-2,246.98%
70.61%
Net Income, GAAP
93.45%
23.82%
-7.65%
Sales/Revenue/Turnover
9.95%
12.85%
0.03%
Total Cash Common Dividend
41.31%
16.03%
24.08%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
233,601
255,562
271,030
256,914
1,017,107
2025
240,550
251,518
280,010
245,348
1,017,427
2026
255,354
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
355
359
142
- -
1,020
2025
4.16
105.57
404.92
- -
766
2026
494
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
99.12
2025
- -
- -
- -
- -
100.02
2026
- -
- -
- -
- -
- -
Similar Companies
Waverunner Capital Inc. (CHM.CN)
The Sustainable Nutrition Group Ltd (TSN.AX)
Suven Pharmaceuticals Limited (SUVENPHAR.BO)
Mankind Pharma Limited (MANKIND.BO)
Syntara Limited (SNT.AX)
Animalcare Group plc (ANCR.L)
Business
Boryung Corporation (003850.KS) engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. The company offers prescription drugs for hypertension including Kanarb (fimasartan), Kanarb Plus (ARB+HCTZ), Dukarb (ARB+CCB), and Tuvero (ARB+statin); dyslipidemia treatments; diabetes medications; central nervous system drugs; oncology drugs such as Gemzar, Genexol, and Xeloda; antibiotics including Maxipime; antiulcerants like Besto (H2RA) and Gelfos M (antacids); and active pharmaceutical ingredients (API). It operates across therapeutic categories encompassing cardiovascular, anti-infective, respiratory, and oncology segments, with exports to nearly 50 countries across six continents including Japan, China, Southeast Asia, the Middle East, Europe, South America, and Africa. Founded in 1957 and headquartered in Seoul, South Korea, at Boryung Building, 136 Changgyeonggung-ro, Jongno-gu, the company previously operated as Boryung Pharmaceutical Co., Ltd. until changing its name to Boryung Corporation in March 2022. Boryung Corporation maintains manufacturing facilities in Ansan and Yesan, employs approximately 1,533 people, and focuses on research and development for chronic disease treatments, incrementally modified drugs, and oncology pipelines. In recent developments, Boryung Corporation invested $10 million in shares of U.S.-based Intuitive Machines Inc. in December 2024 as part of its Humans in Space initiative, following a memorandum of understanding signed in October 2024 and prior investments in Axiom Space. The company received KRW 175 billion in funding from Boryung Partners Co. Ltd. in November 2024 and signed a global contract development and manufacturing organization (CDMO) agreement with Cheplapharm in 2025 to produce and supply Zyprexa tablets to 46 countries. Additionally, it expanded penicillin production facilities and advanced Korean generic anticancer drugs in 2025, while private equity firms Eugene PE and KDB PE agreed to acquire its subsidiary Boryung Biopharma for $231 million in June 2024.